Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07050862 · ClinicalTrials.gov registry record · NA

rTMS for Tobacco Use in Veterans

A NA study, sponsored by VA Office of Research and Development.

Not yet
Registry status
NA
Development phase
56
Enrollment target

NCT07050862: Clinical Trial NA study, sponsored by VA Office of Research and Development.

NCT07050862 is a NA study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07050862, a NA study, has not yet begun recruiting, sponsored by VA Office of Research and Development.

NOT YET RECRUITING
Registry status
NA
Development phase
56 participants
Enrollment target

Study Summary

Cigarette smoking is a significant public health concern for Veterans. Encouraging smoking cessation continues to be a top priority for the Veterans' Administration as Veterans who use tobacco experience negative health effects, including cancer, heart disease, and mental disorders. Despite the efficacy of current evidence-based pharmacotherapies and psychotherapies for smoking cessation, alternative treatments are critically needed. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive form of brain stimulation, US FDA-approved for smoking cessation. In this protocol, the investigators propose comparing the two rTMS protocols (standard TMS vs. precision TMS) to find a better treatment parameter for smoking cessation in Veterans. Identifying an efficacious rTMS protocol would benefit Veterans who want to quit smoking.

Primary Outcome

The investigators will compare the reduction of cigarette consumption between the two treatment groups at the end of the 3-week Repetitive Transcranial Magnetic Stimulation (rTMS) treatment. A higher reduction of CPD means a better treatment result.

Interventions

  • DEVICE Transcranial Magnetic Stimulation
  • DEVICE personalized-image-guided and E-field-modeling dose rTMS (precision TMS)

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2026-07-01
Est. Completion 2030-08-31
Phase NA
VA Office of Research and Development

1,668 total trials

What is known before NCT07050862 opens enrollment

NCT07050862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Transcranial Magnetic Stimulation is the first listed.

NCT07050862 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07050862 about?

NCT07050862 is a clinical study titled "rTMS for Tobacco Use in Veterans". Cigarette smoking is a significant public health concern for Veterans. Encouraging smoking cessation continues to be a top priority for the Veterans' Administration as Veterans who use tobacco experience negative health effects, including cancer, heart disease, and mental disorders. Despite the effi...

What is the current status of trial NCT07050862?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2026-07-01. Estimated completion is 2030-08-31.

What interventions are being tested in trial NCT07050862?

The interventions under investigation include: Transcranial Magnetic Stimulation (DEVICE), personalized-image-guided and E-field-modeling dose rTMS (precision TMS) (DEVICE).

Who is sponsoring clinical trial NCT07050862?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07050862's enrollment target sits among peer trials

56 1262nd of 2000 higher than 737 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02287428 · 56 participants · Phase 1

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  • NCT02923011 · 56 participants · Phase 3

    Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

  • NCT02935283 · 56 participants

    Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders

  • NCT03375866 · 56 participants · NA

    Effects of Mixed Nut Consumption on Satiety and Weight Management

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07050862, the US trial registry maintained by the National Library of Medicine. NCT07050862 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.